Oliver G. Ottmann

Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications

Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.

Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.

Journal: Leukemia & lymphoma
Published: August 02, 2026

Mutational Signatures and Machine Learning for Risk Stratification of Acute Myeloid Leukaemia Based on Targeted Sequencing Data.

Mutational Signatures and Machine Learning for Risk Stratification of Acute Myeloid Leukaemia Based on Targeted Sequencing Data.

Journal: Cancers
Published: April 26, 2026

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.

Journal: Leukemia
Published: February 21, 2025

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: February 08, 2025

Asciminib for Ph+ ALL: a step forward?

Asciminib for Ph+ ALL: a step forward?

Journal: Blood
Published: February 06, 2025

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Journal: Annals of hematology
Published: October 27, 2024

Management of ALL in adults: 2024 ELN recommendations from a European expert panel.

Management of ALL in adults: 2024 ELN recommendations from a European expert panel.

Journal: Blood
Published: December 19, 2023

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.

Journal: American journal of hematology
Published: September 12, 2023

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.

Journal: Blood
Published: July 11, 2023

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.

Journal: Leukemia
Published: December 02, 2022

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.

Journal: Cell
Published: July 17, 2022

Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.

Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.

Journal: PLoS genetics
Published: March 11, 2022
Showing 1-12 of 97

Last Updated: 09/26/2026